| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $17.9M | +54.7% |
| SG&A Expense | $14.9M | +9.5% |
| Operating Income | -$32.8M | -35.7% |
| Pre-tax Income | -$31.1M | -37.5% |
| Income Tax | $0 | -100.0% |
| Net Income | -$27.0M | -46.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $88.9M | +142.0% |
| Current Assets | $89.9M | +135.9% |
| Total Assets | $89.9M | +134.9% |
| Current Liabilities | $6.6M | +27.8% |
| Total Liabilities | $25.5M | +6.2% |
| Stockholders' Equity | $64.4M | +428.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$25.3M | +0.2% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $77.4M | +47.2% |